- Home
- IFRX vs EP Comparison
IFRX vs EP Comparison
Compare IFRX & EP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IFRX
- EP
- Stock Information
- Founded
- IFRX 2007
- EP 1983
- Country
- IFRX Germany
- EP United States
- Employees
- IFRX N/A
- EP N/A
- Industry
- IFRX Biotechnology: Pharmaceutical Preparations
- EP Oil & Gas Production
- Sector
- IFRX Health Care
- EP Energy
- Exchange
- IFRX Nasdaq
- EP Nasdaq
- Market Cap
- IFRX 143.7M
- EP 169.9M
- IPO Year
- IFRX 2017
- EP N/A
- Fundamental
- Price
- IFRX $2.24
- EP $6.14
- Analyst Decision
- IFRX Strong Buy
- EP
- Analyst Count
- IFRX 1
- EP 0
- Target Price
- IFRX $8.00
- EP N/A
- AVG Volume (30 Days)
- IFRX 401.6K
- EP 37.3K
- Earning Date
- IFRX 11-08-2024
- EP 11-14-2024
- Dividend Yield
- IFRX N/A
- EP N/A
- EPS Growth
- IFRX N/A
- EP N/A
- EPS
- IFRX N/A
- EP N/A
- Revenue
- IFRX $187,930.00
- EP $43,254,386.00
- Revenue This Year
- IFRX $435.15
- EP N/A
- Revenue Next Year
- IFRX $180.44
- EP N/A
- P/E Ratio
- IFRX N/A
- EP N/A
- Revenue Growth
- IFRX 177.12
- EP 10.97
- 52 Week Low
- IFRX $1.17
- EP $4.06
- 52 Week High
- IFRX $2.82
- EP $10.99
- Technical
- Relative Strength Index (RSI)
- IFRX 52.76
- EP 37.53
- Support Level
- IFRX $1.93
- EP $6.26
- Resistance Level
- IFRX $2.74
- EP $7.20
- Average True Range (ATR)
- IFRX 0.25
- EP 0.36
- MACD
- IFRX -0.06
- EP -0.17
- Stochastic Oscillator
- IFRX 34.88
- EP 0.00
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
About EP Empire Petroleum Corporation
Empire Petroleum Corp is a conventional oil and natural gas producer with a main focus in the US onshore. The company possesses long-life, mature, producing assets with slow decline profiles in the Permian Basin, Bakken region and central Gulf Coast region, in the states of New Mexico, North Dakota, Montana, Louisiana and Texas. It has production from operated and non-operated wells in Lea County in New Mexico, Bottineau, Renville, Burke, and McKenzie Counties in North Dakota, Richland County in Montana, St. Landry, Beauregard Parishes in Louisiana and Houston, Leon and Madison Counties in Texas.